OTCMKTS:BVNRY Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free BVNRY Stock Alerts $6.92 -0.23 (-3.22%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$6.86▼$6.9250-Day Range$6.92▼$8.5352-Week Range$5.95▼$10.65Volume4,115 shsAverage Volume5,781 shsMarket Capitalization$1.62 billionP/E Ratio7.28Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Bavarian Nordic A/S alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY)Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. Written by Jeffrey Neal JohnsonRead More BVNRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BVNRY Stock News HeadlinesApril 22, 2024 | seekingalpha.comBVNKF Bavarian Nordic A/SApril 18, 2024 | americanbankingnews.comBavarian Nordic A/S (OTCMKTS:BVNRY) Stock Crosses Below Two Hundred Day Moving Average of $7.60April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 16, 2024 | finance.yahoo.comResolutions of the Annual General Meeting 2024 of Bavarian Nordic A/SApril 13, 2024 | msn.comWeekend Warm-up: With Serge Gnabry’s future at Bayern Munich uncertain, Chris Führich and Bayern Munich could be getting close; Bundesliga predictions; Throwing it back to ...April 3, 2024 | msn.comBavarian Nordic launches mpox vaccine in United StatesApril 3, 2024 | msn.comBavarian Nordic expands access to mpox vaccine in USApril 2, 2024 | finance.yahoo.comBavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.April 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 30, 2024 | msn.comNorwegians facing a shortage as Easter nears are hoarding eggs from neighboring SwedenMarch 16, 2024 | msn.comFrankenmuth kicks off the start of Osterbrunnen: Bavarian EasterMarch 14, 2024 | wsj.comNordic Economic Growth to Pick Up This Year, But With DivergenceMarch 14, 2024 | wsj.comNordic Capital Bets on Digital Payments Backing InsurTech One IncMarch 13, 2024 | finance.yahoo.comBavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in SwitzerlandMarch 12, 2024 | globenewswire.comReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchMarch 11, 2024 | msn.comHurry: Nordic Ware’s Spring-Themed Baking Pans Are Up to 45% Off, Just In Time To Celebrate the SeasonMarch 6, 2024 | finanznachrichten.deBavarian Nordic A/S: Bavarian Nordic Publishes Annual Report 2023March 6, 2024 | finance.yahoo.comBavarian Nordic Publishes Annual Report 2023February 25, 2024 | benzinga.comBavarian Nordic Stock (OTC:BVNRY) Dividends: History, Yield and DatesFebruary 23, 2024 | msn.comBavarian Nordic’s chikungunya vaccine secures EMA fast-trackFebruary 23, 2024 | finanznachrichten.deBavarian Nordic A/S: Bavarian Nordic's Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines AgencyFebruary 23, 2024 | finance.yahoo.comBavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines AgencyFebruary 21, 2024 | msn.comBavarian Nordic pulls plug on cancer vaccine programFebruary 21, 2024 | finance.yahoo.comBavarian Nordic delivered record financial results in 2023February 21, 2024 | globenewswire.comBavarian Nordic delivered record financial results in 2023February 12, 2024 | investing.comBavarian Nordic A/S ADR (BVNRY)February 3, 2024 | msn.comMatch awards from Bayern Munich’s 3-1 comeback win against Borussia MönchengladbachSee More Headlines Receive BVNRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:BVNRY CUSIPN/A CIKN/A Webwww.bavarian-nordic.com Phone(453) 326-8383Fax45-3326-8380Employees1,379Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.95 Trailing P/E Ratio7.53 Forward P/E Ratio13.75 P/E GrowthN/ANet Income$214.09 million Net Margins20.80% Pretax Margin12.92% Return on Equity0.07% Return on Assets14.62% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio0.94 Sales & Book Value Annual Sales$1.02 billion Price / Sales1.63 Cash Flow$0.03 per share Price / Cash Flow206.74 Book Value$4.77 per share Price / Book1.50Miscellaneous Outstanding Shares234,290,000Free FloatN/AMarket Cap$1.68 billion OptionableNot Optionable Beta1.50 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Paul John Chaplin MSc (Age 57)Ph.D., CEO & President Comp: $2.09MMr. Henrik Juuel M.Sc. (Age 59)CFO & Executive VP Comp: $1.16MMr. Russell Thirsk M.Sc. (Age 56)Executive VP & COO Mr. Rolf Sass SørensenVice President of Investor Relations & CommunicationsMs. Anu Helena Kerns M.Sc. (Age 52)Executive VP and Chief People & Sustainability Officer Mr. Jean-Christophe May M.B.A. (Age 57)Pharm.D., Executive VP & Chief Commercial Officer Dr. Laurence De Moerlooze Ph.D. (Age 60)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsNeumora TherapeuticsNASDAQ:NMRAInhibrxNASDAQ:INBXSana BiotechnologyNASDAQ:SANARecursion PharmaceuticalsNASDAQ:RXRXFusion PharmaceuticalsNASDAQ:FUSNView All Competitors BVNRY Stock Analysis - Frequently Asked Questions How have BVNRY shares performed in 2024? Bavarian Nordic A/S's stock was trading at $8.7450 at the beginning of 2024. Since then, BVNRY stock has decreased by 18.2% and is now trading at $7.15. View the best growth stocks for 2024 here. Are investors shorting Bavarian Nordic A/S? Bavarian Nordic A/S saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 800 shares, an increase of 700.0% from the March 31st total of 100 shares. Based on an average daily volume of 12,900 shares, the short-interest ratio is presently 0.1 days. View Bavarian Nordic A/S's Short Interest. How were Bavarian Nordic A/S's earnings last quarter? Bavarian Nordic A/S (OTCMKTS:BVNRY) posted its quarterly earnings results on Wednesday, March, 6th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.12. The business earned $353.27 million during the quarter, compared to analysts' expectations of $340.71 million. Bavarian Nordic A/S had a net margin of 20.80% and a trailing twelve-month return on equity of 0.07%. How do I buy shares of Bavarian Nordic A/S? Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BVNRY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bavarian Nordic A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
